Status:
UNKNOWN
Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Pulmonary Hypertension
End-Stage Renal Disease
Eligibility:
All Genders
18+ years
Brief Summary
Remodulin (Treprostenil sodium) is synthetic prostacyclin analog available as a solution for administration in the intravenous route. It is approved for treatment of class I - pulmonary hypertension f...
Detailed Description
After giving informed consent 10 ml of blood will be drawn from the study population at the following occasions. * Baseline measurement immediately before starting HD therapy. * During the hemo-dialy...
Eligibility Criteria
Inclusion
- patients with PAH who receive chronic (more than 3 months) Treprostenil treatment administered intravenously as a single agent therapy who maintain chronic hemo-dialysis therapy. Patients must be in stable condition for at least one month. Patients other than class I PAH will be not included in this study.
Exclusion
- none
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01234571
Start Date
November 1 2010
Last Update
November 4 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.